Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Impressive Q2 Performance Drives Further Guidance Raise At ANI

Firm Now Anticipates 2023 Net Revenue Between $425m And $445m

Executive Summary

Management at ANI has upped its estimates for the second time this year after another impressive quarter, driven by Cortrophin gel and a strong generics performance.

You may also be interested in...



ANI Guidance Raise Can’t Stop Stock Price Slump

Stock prices at ANI Pharmaceuticals dropped 14.8% following its Q3 results announcement, despite a guidance raise from the company, after it noted that competitor supply disruptions seemed to be easing off.

ANI Aims For CGT Top Spot With Two New Launches

ANI Pharmaceuticals has heralded the approval and launch of two new US competitive generic therapies as giving it a joint leadership position in the CGT space.

ANI Revises Its Expectations Up Following Record Revenues

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel